[ad_1]
The two recent FDA registrations, Kalydeco (ivacaftor) and Keytruda (pembrolizumab), for 33 mutations in cystic fibrosis and cancer treatment based on a genetic trait, point to a promising future for precision medicine. The National Cancer Institute (NCI) is conducting the NCI-COG Pediatric MATCH trial, which includes children and adolescents following advanced cancer treatment based on their genetic abnormality. The NCI also plans to support new clinical trials of immunotherapy, antibodies and testing of new cell combinations. molecule, and radiotherapy studies, which include sequencing of tumor samples.
Request a sample of this report: www.coherentmarketinsights.com/insight/request-sample/145
In July 2017, the NCI also launched various precision medicine trials, including lung cancer enrichment marker and cancer alignment badays (ALCHEMIST), the master protocol for lung cancer (MAP-Lung), Molecular Analysis for Treatment Choice (NCI-MATCH), and Molecular Profiling Based on Cancer Therapy (NCI-MPACT).
The cost and time needed to develop new precision drugs is expected to decrease due to the development of the large data badytics and information technology sector. In addition, the development of new precision drugs will help provide the right prescription for improving the patient's health. A multitude of useful and necessary data for bespoke prescription is created by numerous genetic tests and diagnostic tests, which must be performed to provide precision medicines. Doctors are able to provide precision medicine, while large data badysis and computing are able to process, badyze and store the necessary data.
The major market players working on the development of bioinformatics technology for precision medicine research applications are funded by the government. For example, in August 2017, Armonica Technologies, Inc., an Albuquerque-based company, received $ 1.5 million as a catalyst fund. The drugs developed by the manufacturers are difficult to approve and expensive. They are not functional for a large number of people, which has prompted pharmaceutical companies to develop an active drug to cure the disease, which can be done with the help of Big Data Analysis and the IT sector to manufacture Precision drugs.
The key players in the precision medicine market are adopting strategies such as collaboration to strengthen their product portfolio. In 2016, Precision for Medicine, Inc. signed an agreement to acquire ACT Oncology, which will allow the company to gain a foothold in the personalized cancer clinical trial space. In August 2017, Variantyx, a genetic testing company, announced its partnership with FDNA. The FDNA has facial recognition software that facilitates the diagnosis of rare diseases. It is planned to respond to patients' requests and offer them a precision medicine.
For more information on this report, please visit http://www.coherentmarketinsights.com/market-insight/precision-medicine-market-145.
Intomics, Ferrer Incode, Nanostring Technologies, Inc., Pfizer Services, Pfizer, Novartis AG, Teva Pharmaceuticals, Merck & Co., Inc., Qiagen N.V. and Quest Diagnostics.
Source link
